关注
Annalisa Cespiati
Annalisa Cespiati
未知所在单位机构
在 unimi.it 的电子邮件经过验证
标题
引用次数
引用次数
年份
Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver
P Dongiovanni, S Stender, A Pietrelli, RM Mancina, A Cespiati, S Petta, ...
Journal of internal medicine 283 (4), 356-370, 2018
3272018
Prevalence and risk factors of significant fibrosis in patients with nonalcoholic fatty liver without steatohepatitis
S Pelusi, A Cespiati, R Rametta, G Pennisi, V Mannisto, C Rosso, ...
Clinical Gastroenterology and Hepatology 17 (11), 2310-2319. e6, 2019
912019
PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients
P Dongiovanni, M Meroni, G Baselli, RM Mancina, M Ruscica, M Longo, ...
Journal of lipid research 60 (6), 1144-1153, 2019
542019
Rare ATG7 genetic variants predispose patients to severe fatty liver disease
GA Baselli, O Jamialahmadi, S Pelusi, E Ciociola, F Malvestiti, M Saracino, ...
Journal of Hepatology 77 (3), 596-606, 2022
502022
Pain and frailty in hospitalized older adults
I Ardoino, C Franchi, A Nobili, PM Mannucci, O Corli
Pain and therapy 9, 727-740, 2020
332020
Impact of sarcopenia and myosteatosis in non-cirrhotic stages of liver diseases: similarities and differences across aetiologies and possible therapeutic strategies
A Cespiati, M Meroni, R Lombardi, G Oberti, P Dongiovanni, ...
Biomedicines 10 (1), 182, 2022
202022
Interaction between lifestyle changes and PNPLA3 genotype in NAFLD patients during the COVID-19 lockdown
F Cinque, A Cespiati, R Lombardi, A Costantino, G Maffi, F Alletto, ...
Nutrients 14 (3), 556, 2022
142022
Genetics and epigenetics in the clinic: precision medicine in the management of fatty liver disease
A Cespiati, NA Youngson, A Tourna, L Valenti
Current Pharmaceutical Design 26 (10), 998-1009, 2020
142020
Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled …
A Cespiati, S Petta, R Lombardi, V Di Marco, V Calvaruso, C Bertelli, ...
Digestive and Liver Disease 53 (10), 1301-1307, 2021
102021
Usefulness of fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity
R Lombardi, VL Mura, A Cespiati, F Iuculano, G Sigon, G Pallini, M Proietti, ...
Internal and emergency medicine 17 (6), 1739-1749, 2022
82022
Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both
E Crisafulli, G Sartori, A Vianello, F Busti, A Nobili, PM Mannucci, D Girelli
Internal and Emergency Medicine 18 (2), 523-534, 2023
62023
Prevalence and determinants of liver disease in relatives of Italian patients with advanced MASLD
S Pelusi, L Ronzoni, J Rondena, C Rosso, G Pennisi, P Dongiovanni, ...
Clinical Gastroenterology and Hepatology, 2024
52024
An Overview of hepatocellular carcinoma surveillance focusing on non-cirrhotic NAFLD patients: A challenge for physicians
A Cespiati, F Cinque, M Meroni, R Lombardi, P Dongiovanni, ...
Biomedicines 11 (2), 586, 2023
52023
Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors
R Lombardi, A Mantovani, A Cespiati, P Francione, G Maffi, E Del Zanna, ...
Digestive and Liver Disease 56 (4), 551-558, 2024
42024
Anemia management and transfusion strategy in internal medicine units: Less is more
D Blanca, G Parrella, D Consonni, S Villa, G Ceriani, A Cespiati, G Figini, ...
European Journal of Internal Medicine 115, 48-54, 2023
42023
Subclinical and clinical atherosclerosis in non-alcoholic fatty liver disease is associated with the presence of hypertension
F Cattazzo, R Lombardi, A Mantovani, M Bevilacqua, M Zoncapè, LI Prat, ...
Nutrition, Metabolism and Cardiovascular Diseases 32 (12), 2839-2847, 2022
42022
Old-fashioned and newly discovered biomarkers: The future of NAFLD-related HCC screening and monitoring
R Piciotti, M Longo, A Agresta, E Paolini, A Cespiati, M Meroni, ...
Hepatoma Res 8, 37, 2022
42022
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis
S Di Cola, G D’Amico, P Caraceni, F Schepis, S Loredana, P Lampertico, ...
Journal of Hepatology, 2024
32024
Nutritional and Lifestyle Therapy for NAFLD in People with HIV
F Cinque, A Cespiati, R Lombardi, G Guaraldi, G Sebastiani
Nutrients 15 (8), 1990, 2023
32023
The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value
E Paolini, M Longo, M Meroni, G Tria, A Cespiati, R Lombardi, S Badiali, ...
Frontiers in Nutrition 10, 1101341, 2023
32023
系统目前无法执行此操作,请稍后再试。
文章 1–20